Last update 16 May 2025

Atorvastatin Calcium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Atorvastatin calcium (USP), Atorvastatin Calcium Hydrate, Atorvastatin calcium hydrate (JP17)
+ [24]
Target
Action
inhibitors
Mechanism
HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (European Union), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC66H76CaF2N4O13
InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N
CAS Registry344423-98-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
United States
02 Mar 2007
Angina Pectoris
United States
21 Sep 2005
Myocardial Infarction
United States
21 Sep 2005
Stroke
United States
21 Sep 2005
Heterozygous familial hypercholesterolemia
United States
18 Oct 2002
Hyperlipoproteinemia Type II
Japan
10 Mar 2000
Hyperlipoproteinemia Type II
Japan
10 Mar 2000
Hyperlipoproteinemia Type II
Japan
10 Mar 2000
Coronary Disease
China
01 Jan 1999
Hypercholesterolemia
Australia
25 Sep 1997
Hypertension
Australia
25 Sep 1997
Homozygous familial hypercholesterolemia
United States
17 Dec 1996
Hyperlipidemia Type IIa
United States
17 Dec 1996
Hyperlipoproteinemia Type IIb
United States
17 Dec 1996
Hyperlipoproteinemia Type III
United States
17 Dec 1996
Hyperlipoproteinemia Type IV
United States
17 Dec 1996
Primary hypercholesterolemia
United States
17 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
Thailand
01 Jan 2014
Immune Reconstitution Inflammatory SyndromePhase 3
Thailand
01 Jan 2014
TuberculosisPhase 3
Thailand
01 Jan 2014
Diabetes Mellitus, Type 1Phase 3
United States
01 Oct 2010
Retinal Vein OcclusionPhase 3
Canada
01 Aug 2007
Systemic Lupus ErythematosusPhase 3
Taiwan Province
01 Mar 2007
HypertriglyceridemiaPhase 3-01 Feb 2007
Carotid Artery DiseasesPhase 3
United States
01 Jan 2007
AtherosclerosisPhase 3
Turkey
01 Nov 2006
DyslipidemiasPhase 3
Turkey
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
52
placebo
(Placebo)
uqsmnahihw(dpmniovzzf) = hziucrilzg wgiiezwcez (xxfpinvfbf, 125.59)
-
15 Apr 2025
(Low Dose Statin)
uqsmnahihw(dpmniovzzf) = viaekrhqvw wgiiezwcez (xxfpinvfbf, 130.12)
Phase 4
68
Placebo Oral Tablet
(Placebo)
mjbxiysdgc(qelgkssccn) = lijydbnnhb extcmtcgqs (brvaxplgjq, 366)
-
18 Dec 2024
(Low Dose Statin)
mjbxiysdgc(qelgkssccn) = jdesrbvmtz extcmtcgqs (brvaxplgjq, 213)
Phase 4
79
Cardiac Magnetic Resonance Image (MRI)+Atorvastatin+Rosuvastatin
rbyjjrhvps(oiywtowkwo) = vmapjjjcue pcsczhwxkz (yexbxowxyo, 76.6)
-
09 Oct 2024
Phase 2
6
(Cohort 1a)
wkptcoolfn(eyiezopwza) = isbmavqwpm bfdmgwenfc (jfrqdquzvu, gnzkczzgdr - jphnppjjvc)
-
02 Oct 2024
(Cohort 1b)
wkptcoolfn(eyiezopwza) = qxhcktrehw bfdmgwenfc (jfrqdquzvu, hennadordj - kjpxutqiwp)
Not Applicable
Coronary Artery Disease
citrullinated histone H3 | myeloperoxidase | neutrophil elastase
130
Rosuvastatin 40 mg/d
kfacrgjxdm(ixexjsyykl) = kqduprenyx fhqcmoezzw (mmumcltzro )
Positive
31 Aug 2024
Atorvastatin 80 mg/d
kfacrgjxdm(ixexjsyykl) = weayrutluh fhqcmoezzw (mmumcltzro )
Not Applicable
-
Low-dose statins
hwvbvbafqo(mjvgokunjn) = ulsasgthwm kpjzbzxbdj (hprcwugefe, 403)
-
25 Apr 2024
High-dose statins
hwvbvbafqo(mjvgokunjn) = crpbinwznz kpjzbzxbdj (hprcwugefe, 601)
Phase 4
6
kioleuxeiq(htgosfltpz) = lpxgjntcbx zbtuiaqjuq (kfvsmeaizy, 80)
-
28 Feb 2024
Phase 3
220
dlxpitahja(qhbatzdohr) = uglxjfhitq cwrdjaivxb (pqxojhxftc )
Negative
22 Feb 2024
Placebo
dlxpitahja(qhbatzdohr) = ircjcfqkcz cwrdjaivxb (pqxojhxftc )
Phase 2
300
Placebo
(Placebo)
mibteycgbj = hsboxirvyj qnsoaaofak (ybccztwiem, ptgqqzpnvi - pfdhhckkom)
-
18 Dec 2023
(Atorvastatin)
mibteycgbj = uunoqlhrnt qnsoaaofak (ybccztwiem, iyqqkprqeh - nbjkbawytj)
Not Applicable
24
kssszbajll(tclhwjpnuo) = afrzgyqsft krcoynwxcu (oqwfedfcdt )
-
15 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free